Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Payables (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Payables for 7 consecutive years, with $24.4 million as the latest value for Q4 2025.

  • Quarterly Payables fell 2.93% to $24.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.4 million through Dec 2025, down 2.93% year-over-year, with the annual reading at $24.4 million for FY2025, 2.93% down from the prior year.
  • Payables hit $24.4 million in Q4 2025 for Immunocore Holdings, up from $23.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $88.1 million in Q4 2022 to a low of $10.1 million in Q4 2021.
  • Historically, Payables has averaged $31.3 million across 5 years, with a median of $23.9 million in 2025.
  • Biggest five-year swings in Payables: surged 771.12% in 2022 and later plummeted 79.79% in 2023.
  • Year by year, Payables stood at $10.1 million in 2021, then soared by 771.12% to $88.1 million in 2022, then tumbled by 79.79% to $17.8 million in 2023, then surged by 41.03% to $25.1 million in 2024, then dropped by 2.93% to $24.4 million in 2025.
  • Business Quant data shows Payables for IMCR at $24.4 million in Q4 2025, $23.0 million in Q3 2025, and $23.9 million in Q2 2025.